IL28B polymorphism predict the response to chronic hepatitis C treatment

Öz

Purpose: Hepatitis C is an important medical problem which causes chronic liver disease. 170 million people are believed to be infected throughout the world. While spontaneous hepatitis C virus (HCV) clearance occurs in almost 30 % of patients with hepatitis C, it becomes chronic in 70 % which may progress to cirrhosis or hepatocellular carcinoma (HCC). In recent years, IL28B polymorphism on chromosome 19q13 has been suggested as the most important predictor among the host factors for sustained virologic response (SVR). In the present study, we aimed to evaluate the effect of IL28B gene polymorphism on conventional treatment response.

Materials and methods: Totally 95 patients treated with a combination of peginterferon and ribavirin during 48 weeks were included the study. Age, gender, AST and ALT levels, insulin and fasting glucose levels, BMI, fibrosis levels on liver biopsy and 0-4-12-24-48-72-week HCV RNA values were recorded.

Results: In the study group of 95 HCV-infected patients, the mean age was 52.4±11 years. SVR was observed in 54 (%56.8) of patients at the follow up. Demographical and laboratory variables were similar in SVR and non-SVR groups. IL28B SNP rs12979860 was positive in CC 26 (47.2 %), CT 25 (45.4%) and TT 4 (7.2 %) patients with SVR group and in CC 4 (10 %), CT 23 (57.5 %), TT 13 (32.5 %) patients with non-SVR group.

Conclusion: SVR was achieved more likely in HCV genotype 1 rs12979860, and treatment decision may be changed based on the degree of liver disorder. In this regard, new studies involving larger patient population from our country are needed.    

Anahtar Kelimeler

• Hepatitis C,interleukin-28B,genetic variation

Kronik hepatit C tedavisine yanıtı tahmin etmede IL28B gen polimorfizmi

Öz

Amaç: Hepatit C, kronik karaciğer hastalığına neden olan büyük bir sağlık sorunudur. Dünya’da 170 milyon insanın enfekte olduğu düşünülmektedir. Hepatit C’li hastaların yaklaşık % 30’unda spontan viral klirens meydana gelirken, % 70’inde hastalık kronikleşmekte, bir kısmında siroz ve hepatosellüler kanser gelişebilmektedir. Konak faktörleri içinde kalıcı viral yanıtın en iyi belirleyicisi, son yıllarda ortaya konan kromozom 19q13 üzerindeki IL28 B polimorfizmidir. Çalışmadaki amacımız bölgemizdeki hasta populasyonunda IL28B gen polimorfizminin tedaviye yanıta olan etkisini ortaya koymaktır.

Gereç ve yöntem: Çalışmaya 48 haftalık peginterferon ve ribavirin tedavisi ve sonrasındaki 24. haftada kontrole gelen 95 hasta alındı. Hastaların tedavi öncesi yaş, cinsiyet, AST, ALT değerleri, insülin ve açlık glukozu, karaciğer biyopsisinde fibrozis düzeyleri,- 0-4-12-24-48-72. hafta HCV RNA değerleri kaydedildi.

Bulgular: Hastaların yaş ortalaması 52,4±11 idi. Çalışma sonunda hastaların 54’ünde (%56.8) kalıcı viral yanıt gözlendi. Tedaviye yanıta etki eden demografik ve laboratuvar özellikleri kalıcı viral yanıt ve kalıcı olmayan viral yanıt gruplarında benzerdi. Kalıcı viral yanıt olan hastalarda IL 28B SNP rs12979860 polimorfizmine bakıldığında; CC 26 (% 47.2), CT 25 (% 45.4), TT 4 (% 7.2) hastada saptandı. Kalıcı viral yanıt olmayan hastalarda IL 28B SNP rs12979860 polimorfizmi; CC 4 ( % 10) ,CT 23 (% 57.5), TT 13 (% 32.5) hastada saptandı.

Sonuç: HCV genotip 1 rs12979860 CC genotipte kalıcı viral yanıt oranının yüksek olması nedeniyle karaciğer hastalığının şiddetine dayalı tedavi kararını değiştirebilir. Bu konuda ülkemizde daha büyük hasta populasyonlarını içeren çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

• Hepatit C,interlökin-28B,, gene polimorfizmiene polimorfizmi

Kaynakça

1. Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol. 2015;7:2676–2680.
2. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect.2015;21:1020-1026.
3. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 17;461:399-401.
4. Altuglu I, Soyler I, Ozacar T, Erensoy S. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis. 2008 ;12:239-244.
5. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-1104.
6. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.
7. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-129.
8. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol. 2007 ;22:832-836.

9. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954-60.
10. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801.
11. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338-1345.
12. Stattermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:344-350.
13. Echeverría N, Chiodi D, López P, Sanchez Ciceron A, Angulo J, López-Lastra M, et al. IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients.Virol J. 2018;15:40.
14. Ramos JA, Ramos AL, Hoffmann L, Perez Rde M, Coelho HS, Urmenyi TP, et al. A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin. Mem Inst Oswaldo Cruz. 2012;107:888-892.
15. Świątek-Kościelna B, Kałużna E, Strauss E, Nowak J, Bereszyńska I, Gowin E, et al. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.World J Gastroenterol. 2017;23:3815-3824.